Before clinical milestones are reached, before outcomes are measured, and before new standards of care are established, there is research. Research is the foundation of meaningful progress in oncology.
At Roswell Park Comprehensive Cancer Center, discovery is fully integrated with patient care—from laboratory investigation to early-phase and practice-changing clinical trials that only an NCI-designated comprehensive cancer center can offer.
Our most recent National Cancer Institute core grant review resulted in an exceptional rating —the highest possible — a testament to the strength of our research enterprise, the quality of our multidisciplinary clinical programs, and the rigor with which we pursue innovation.
The following successes highlight areas of progress that underscore Roswell Park’s role in advancing care for patients locally and globally. We are shaping the future of oncology as a destination center for the most complex cancer cases.
Cast Your Vote
A novel CAR T-cell therapy available only at Roswell Park Comprehensive Cancer Center is leveraging genome-editing technology to target the glypican-3 (GPC3) protein, which is often expressed in hepatocellular carcinoma (hepatoma) liver cancers — but rarely in healthy tissue.
Learn More
Andrew Fabiano, MD, MBA, FAANS, Chair of the Department of Neurosurgery, Director of the Neuro-Oncology Program and Director of the Spinal Oncology Center, says his team has unique expertise with tumors that are difficult to treat.
Learn More
A phase 1 clinical trial underway exclusively at Roswell Park Comprehensive Cancer Center in Buffalo, N.Y., is evaluating a new chimeric antigen receptor (CAR) T-cell therapy that could dramatically transform the treatment of relapsed or refractory acute myeloid leukemia (AML).
Learn MoreIt’s important to us that patients understand the importance of receiving care at a center that can help them achieve the best possible outcomes, and many turn to national rankings for this guidance. That is why your vote for Roswell Park Comprehensive Cancer Center in the U.S. News & World Report’s Best Hospitals for Cancer expert opinion survey matters. Voting is now open! Cast your vote before closing date in March 2026.
Board-certified physicians in one of several cancer subspecialties who are registered as Doximity users are eligible to vote in the cancer category. You can register on Doximity at any time to vote during the voting period.
Being listed in U.S. News & World Report Best Hospitals is an honor and highlights the expertise of our faculty and staff who provide advanced care for the patients and families who need it most. Only a small percentage of physicians cast a vote, so your vote matters!
If eligible and registered on Doximity, you will receive an email from Doximity about the survey, or log on to Doximity during the survey period of late February to March. Once logged in, you will see a prompt on the homepage to click to take the survey.
BROADCASTMED